Mechanisms underlying Myocarditis

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 2, 2006, Pages 207-212

  Rose, Noel R ^a   Čiháková, Daniela ^a   Barin, Jobert G ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; CARDIAC MYOSIN; CYTOKINE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADENOVIRUS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B; CYTOMEGALOVIRUS; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; HEART FAILURE; HEART PROTECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; MOUSE; MYOCARDITIS; NONHUMAN; PARVOVIRUS; PATHOPHYSIOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

EID: 33748506506     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.05.008     Document Type: Review

References (42)

1. Kyto V., et al. Diagnosis and presentation of fatal myocarditis. Hum. Pathol. 36 (2005) 1003-1007
2. Bowles N.E., et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J. Am. Coll. Cardiol. 42 (2003) 466-472
3. Mason J.W., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 333 (1995) 269-275
4. Bowles N.E., and Vallejo J. Viral causes of cardiac inflammation. Curr. Opin. Cardiol. 18 (2003) 182-188
5. Huber S.A. Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimmunity 39 (2006) 55-61
6. Wolfgram L.J., et al. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J. Immunol. 136 (1986) 1846-1852
7. Herskowitz A., et al. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains. J. Am. Coll. Cardiol. 9 (1987) 1311-1319
8. Alvarez F.L., et al. Heart-specific autoantibodies induced by Coxsackievirus B3: identification of heart autoantigens. Clin. Immunol. Immunopathol. 43 (1987) 129-139
9. Neumann D.A., et al. Induction of multiple heart autoantibodies in mice with coxsackievirus B3- and cardiac myosin-induced autoimmune myocarditis. J. Immunol. 152 (1994) 343-350
10. Neu N., et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J. Immunol. 139 (1987) 3630-3636
11. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99 (1999) 1091-1100
12. Fairweather D., et al. Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin. Immunology 94 (1998) 263-270
13. Lenzo J.C., et al. Characterisation of murine cytomegalovirus myocarditis: cellular infiltration of the heart and virus persistence. J. Mol. Cell. Cardiol. 34 (2002) 629-640
14. Rose N.R., et al. Postinfectious autoimmunity: two distinct phases of coxsackievirus B3-induced myocarditis. Ann. N. Y. Acad. Sci. 475 (1986) 146-156
15. Donermeyer D.L., et al. Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J. Exp. Med. 182 (1995) 1291-1300
16. Pummerer C.L., et al. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J. Clin. Invest. 97 (1996) 2057-2062
17. Afanasyeva M., et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am. J. Pathol. 159 (2001) 193-203
18. Lane J.R., et al. Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol 151 (1993) 1682-1690
19. Fichtner-Feigl S., et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12 (2006) 99-106
20. Čiháková D., et al. Opposite effects of IL-4 and IL-13 in experimental autoimmune myocarditis (EAM). Clin. Immunol. 1 Suppl. 192 (2005) 219
21. Afanasyeva M., et al. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation 104 (2001) 3145-3151
22. Afanasyeva M., et al. Impaired up-regulation of CD25 on CD4+ T cells in IFN-gamma knockout mice is associated with progression of myocarditis to heart failure. Proc. Natl. Acad. Sci. U S A 102 (2005) 180-185
23. Dalton D.K., et al. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J. Exp. Med. 192 (2000) 117-122
24. Barin J.G., et al. Thyroid-specific expression of IFN-gamma limits experimental autoimmune thyroiditis by suppressing lymphocyte activation in cervical lymph nodes. J. Immunol. 170 (2003) 5523-5529
25. Furlan R., et al. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167 (2001) 1821-1829
26. Jones L.S., et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J. Immunol. 158 (1997) 5997-6005
27. Refaeli Y., et al. Interferon gamma is required for activation-induced death of T lymphocytes. J. Exp. Med. 196 (2002) 999-1005
28. Fairweather D., et al. Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am. J. Pathol. 165 (2004) 1883-1894
29. Corradi D., et al. Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum. Pathol. 35 (2004) 1160-1163
30. Patella V., et al. Eosinophil granule proteins activate human heart mast cells. J. Immunol. 157 (1996) 1219-1225
31. Felix S.B., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J. Am. Coll. Cardiol. 39 (2002) 646-652
32. Frustaci A., et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107 (2003) 857-863
33. Wang Y., et al. Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice. J. Am. Coll. Cardiol. 36 (2000) 1992-1999
34. Maisch B., et al. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz 29 (2004) 624-636
35. Sliwa K., et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am. J. Cardiol. 90 (2002) 1118-1122
36. Gullestad L., et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 112 (2005) 3408-3414
37. Pauschinger M., et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur. J. Heart Fail. 7 (2005) 444-452
38. Azuma R.W., et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc. Res. 64 (2004) 412-420
39. Liu W., et al. Effects of adenovirus-mediated gene transfer of ICOSIg and CTLA4Ig fusion protein on experimental autoimmune myocarditis. Autoimmunity 39 (2006) 83-92
40. Mann D.L., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
41. Kuhl U., et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107 (2003) 2793-2798
42. Kaya Z., et al. Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 168 (2002) 1552-1556